RhumbLine Advisers
DRUG

RhumbLine Advisers’s Bright Minds Biosciences DRUG Stock Holding History

RhumbLine Advisers’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$613K Buy
8,733
+971
+13% +$76.2K ﹤0.01% 2628
2026
Q1 		$566K Buy
7,762
+1,826
+31% +$147K ﹤0.01% 2539
2025
Q4 		$463K Sell
5,936
-640
-10% -$42.8K ﹤0.01% 2710
2025
Q3 		$399K Sell
6,576
-36
-0.5% -$1.4K ﹤0.01% 2842
2025
Q2 		$173K Buy
+6,612
New +$198K ﹤0.01% 3307

Other funds holding DRUG

JT
Jupiter Topco New York $245B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

RhumbLine Advisers's DRUG Position: Q2 2026 in Review

RhumbLine Advisers increased its Bright Minds Biosciences (DRUG) stake by 13% in Q2 2026, buying an estimated $76.2K and bringing the position to 8,733 shares worth $613K. The position accounts for ﹤0.01% of the portfolio, ranked #2628.

RhumbLine Advisers first reported a position in DRUG in Q2 2025 and has held it in 5 quarters since. 99 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • RhumbLine Advisers held 8,733 shares of Bright Minds Biosciences worth $613K as of Q2 2026.
  • RhumbLine Advisers bought 971 Bright Minds Biosciences shares in Q2 2026, an estimated $76.2K.
  • Bright Minds Biosciences made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2628 holding.
  • RhumbLine Advisers first reported a position in Bright Minds Biosciences in Q2 2025 and has held it in 5 quarters since.
  • 99 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.